Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
105,778,869
-
Shares change
-
-6,209,528
-
Total reported value, excl. options
-
$137,125,383
-
Value change
-
-$10,782,201
-
Put/Call ratio
-
76%
-
Number of buys
-
68
-
Number of sells
-
-91
-
Price
-
$1.30
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2023
204 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2023.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105,778,869 shares
of 294,683,714 outstanding shares and own 36% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (17,052,440 shares), BlackRock Inc. (15,888,976 shares), VANGUARD GROUP INC (12,398,412 shares), Rokos Capital Management LLP (6,474,348 shares), CITADEL ADVISORS LLC (4,495,013 shares), CREDIT SUISSE AG/ (3,700,000 shares), RENAISSANCE TECHNOLOGIES LLC (3,067,496 shares), GEODE CAPITAL MANAGEMENT, LLC (2,855,752 shares), ACADIAN ASSET MANAGEMENT LLC (2,821,980 shares), and STATE STREET CORP (2,655,627 shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.